AIM ImmunoTech Financials
| AIM Stock | USD 0.23 0.02 9.52% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Debt Equity Ratio | 0.0238 | 0.0251 |
|
| |||||
| Current Ratio | 1.6 | 1.6824 |
|
|
Investors should never underestimate AIM ImmunoTech's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor AIM ImmunoTech's cash flow, debt, and profitability to make informed and accurate decisions about investing in AIM ImmunoTech.
Net Income |
|
AIM | Select Account or Indicator |
Understanding current and past AIM ImmunoTech Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of AIM ImmunoTech's financial statements are interrelated, with each one affecting the others. For example, an increase in AIM ImmunoTech's assets may result in an increase in income on the income statement.
AIM ImmunoTech Stock Summary
AIM ImmunoTech competes with Aptorum Group, Biocardia, Virax Biolabs, Revelation Biosciences, and Kiora Pharmaceuticals. AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida. Aim Immunotech operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 21 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NYSE MKT Exchange |
| ISIN | US00901B1052 |
| CUSIP | 00901B105 42366C103 42366C301 42366C509 |
| Location | Florida; U.S.A |
| Business Address | 2117 SW Highway |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | aimimmuno.com |
| Phone | 352 448 7797 |
| Currency | USD - US Dollar |
AIM ImmunoTech Key Financial Ratios
| Return On Equity | -1.55 | ||||
| Operating Margin | (73.88) % | ||||
| Price To Sales | 72.93 X | ||||
| Revenue | 202 K | ||||
| Gross Profit | (715 K) |
AIM ImmunoTech Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 13.8M | 20.2M | 64.6M | 40.5M | 19.4M | 29.4M | |
| Other Current Liab | 214K | 672K | 438K | 806K | 1.8M | 1.3M | |
| Net Debt | 4.9M | (36.2M) | (31.9M) | (26.2M) | (4.7M) | (5.0M) | |
| Retained Earnings | (328.1M) | (342.0M) | (361.1M) | (380.5M) | (409.5M) | (389.0M) | |
| Accounts Payable | 472K | 383K | 198K | 377K | 6.4M | 6.8M | |
| Cash | 1.5M | 38.5M | 32.1M | 27.1M | 5.4M | 10.3M | |
| Other Current Assets | 848K | 184K | 304K | 455K | 604K | 528.6K | |
| Total Liab | 7.3M | 3.3M | 820K | 2.0M | 9.1M | 9.6M | |
| Total Current Assets | 10.4M | 40.3M | 50.2M | 36.3M | 14.6M | 20.9M | |
| Short Term Debt | 252K | 47K | 37K | 178K | 446K | 423.7K | |
| Intangible Assets | 1.2M | 1.5M | 2.0M | 1.9M | 2.3M | 1.3M | |
| Net Receivables | 820K | 1.1M | 1.6M | 1.7M | 1.2M | 747.1K | |
| Common Stock | 33K | 49K | 10K | 42K | 48K | 89.5K |
AIM ImmunoTech Key Income Statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Revenue | 140K | 163K | 135K | 141K | 202K | 386.8K | |
| Gross Profit | (753K) | (643K) | (715K) | (19.8M) | 160K | 168K | |
| Operating Income | (12.4M) | (15.2M) | (18.8M) | (19.9M) | (31.9M) | (30.3M) | |
| Ebit | (11.5M) | (13.7M) | (19.1M) | (19.4M) | (31.9M) | (30.3M) | |
| Ebitda | (10.7M) | (13.0M) | (18.3M) | (19.9M) | (31.7M) | (30.1M) | |
| Cost Of Revenue | 893K | 806K | 850K | 19.9M | 42K | 39.9K | |
| Income Before Tax | (9.5M) | (14.4M) | (19.1M) | (19.4M) | (29.0M) | (27.5M) | |
| Net Income | (10.8M) | (16.3M) | (21.5M) | (21.1M) | (29.0M) | (27.5M) | |
| Income Tax Expense | 1.3M | 1.9M | 2.4M | 1.6M | 1.9M | 1.3M | |
| Research Development | 4.7M | 5.7M | 7.7M | 7.0M | 10.9M | 6.9M | |
| Interest Expense | 427K | 672K | 67K | 478K | 549.7K | 281.1K |
AIM ImmunoTech Key Cash Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 1.2M | 37.0M | (6.4M) | (5.0M) | (21.6M) | (20.5M) | |
| Free Cash Flow | (9.4M) | (11.0M) | (14.6M) | (16.4M) | (21.9M) | (20.8M) | |
| Depreciation | 792K | 733K | 775K | 256K | 238K | 226.1K | |
| Other Non Cash Items | 255K | 1.8M | 4.2M | 964K | 310K | 316K | |
| Capital Expenditures | 365K | 595K | 633K | 271K | 585K | 732.3K | |
| Net Income | (9.5M) | (14.4M) | (19.1M) | (19.4M) | (29.0M) | (27.5M) | |
| End Period Cash Flow | 1.5M | 38.5M | 32.1M | 27.1M | 5.4M | 5.2M |
AIM Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining AIM ImmunoTech's current stock value. Our valuation model uses many indicators to compare AIM ImmunoTech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across AIM ImmunoTech competition to find correlations between indicators driving AIM ImmunoTech's intrinsic value. More Info.AIM ImmunoTech is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, AIM ImmunoTech's Return On Equity is very stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value AIM ImmunoTech by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.AIM ImmunoTech Systematic Risk
AIM ImmunoTech's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. AIM ImmunoTech volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on AIM ImmunoTech correlated with the market. If Beta is less than 0 AIM ImmunoTech generally moves in the opposite direction as compared to the market. If AIM ImmunoTech Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one AIM ImmunoTech is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of AIM ImmunoTech is generally in the same direction as the market. If Beta > 1 AIM ImmunoTech moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in AIM ImmunoTech Stock are looking for potential investment opportunities by analyzing not only static indicators but also various AIM ImmunoTech's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of AIM ImmunoTech growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
AIM ImmunoTech December 2, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of AIM ImmunoTech help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of AIM ImmunoTech. We use our internally-developed statistical techniques to arrive at the intrinsic value of AIM ImmunoTech based on widely used predictive technical indicators. In general, we focus on analyzing AIM Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build AIM ImmunoTech's daily price indicators and compare them against related drivers.
| Information Ratio | (0.13) | |||
| Maximum Drawdown | 34.24 | |||
| Value At Risk | (7.41) | |||
| Potential Upside | 8.33 |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AIM ImmunoTech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AIM ImmunoTech. If investors know AIM will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AIM ImmunoTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.47) | Revenue Per Share 0.004 | Quarterly Revenue Growth 0.19 | Return On Assets (0.80) | Return On Equity (1.55) |
The market value of AIM ImmunoTech is measured differently than its book value, which is the value of AIM that is recorded on the company's balance sheet. Investors also form their own opinion of AIM ImmunoTech's value that differs from its market value or its book value, called intrinsic value, which is AIM ImmunoTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AIM ImmunoTech's market value can be influenced by many factors that don't directly affect AIM ImmunoTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AIM ImmunoTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if AIM ImmunoTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AIM ImmunoTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.